Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 318

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 318
---
 will be materially harmed. Even if the Company
completes the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent the Company from obtaining clinical trial and marketing approvals for the commercialization
of some or all of its product candidates. As a result, the Company cannot predict when, or if, and in which territories, it will obtain marketing approval to commercialize a product candidate.

The Company is subject to certain risks and uncertainties that the Company believes could have a material adverse effect on its future financial position or
results of operations. As of the date of issuance of the financial statements, the Company is not aware of any specific event or circumstance that would require it to update its estimates, judgments, or the carrying value of its assets or
liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the financial statements as soon as they become known. Actual results could differ from those estimates, and any such
differences may be material to the Company’s financial statements.

The Company is subject to regulation and enforcement by the federal government
and by authorities in state and foreign jurisdictions in which the Company conducts business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security laws and regulations. If the
Company’s operations are found to be in violation of any such laws or government regulations that apply to use, the Company may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the
curtailment or restructuring of operations and exclusion from participation in federal and state healthcare programs.

Cash and Cash Equivalents

The Company’s cash and cash equivalents consist of all highly liquid investments deposited with banks, including money market funds. The
money market fund policies require the weighted average maturity of the fund’s securities holdings not to exceed 90 days.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to significant concentration of credit risk consist primarily of cash and
cash equivalents and accounts receivable. The Company’s cash and cash equivalents are generally held with large financial institutions. Certain deposits held with these financial institutions are in excess of the amount of FDIC insured limits
provided on such deposits.

F-9

B ILLIONT OO NE, INC. Notes to Financial Statements As of December 31, 2023 and 2024, no customers represented more than 10% of accounts receivable, and for the years ended